Testing an experimental drug with chemo for newly diagnosed extensive-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an investigational drug called BNT327, given with standard chemotherapy, for people newly diagnosed with extensive-stage small cell lung cancer. The goal is to see if adding this drug improves outcomes compared to chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have extensive-stage small cell lung cancer (cancer that has spread beyond one lung or to other parts of the body), confirmed by a biopsy or other test.
- You have not received any previous systemic treatment (like chemotherapy or targeted drugs) for extensive-stage SCLC. (If you were treated for limited-stage cancer in the past, it must have been at least 6 months since your last treatment.)
- You have at least one tumor that can be measured on a scan (like a CT or MRI) and that hasn't been previously treated with radiation or other local therapy.
- You are able to take care of yourself (ECOG 0 or 1) – meaning you're up and about, able to do light work or all usual activities.
- You have adequate blood counts and organ function (determined by routine blood tests), and you don't have uncontrolled high blood pressure, diabetes, serious wounds, or active bleeding risk.
- You have no untreated, symptomatic brain tumors larger than 2 cm, and no known spread of cancer to the lining of the brain or spinal cord (leptomeningeal metastases).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
This trial tests combining benmelstobart (a type of immunotherapy), anlotinib (a targeted blood vessel blocker), and standard chemotherapy as the very first treatment for extensive-stage small cell lung cancer (cancer that has spread widely). It aims to see if this combination works better than current options.
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
This trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with extensive-stage small cell lung cancer. It is for those who have not had treatment for this stage yet.
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.